Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Theodore S. Hong(Massachusetts General Hospital), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Thomas F. DeLaney(Massachusetts General Hospital), Kenneth K. Tanabe(Harvard University), Ronald S. Arellano(Massachusetts General Hospital), Milind Javle(The University of Texas MD Anderson Cancer Center), Lipika Goyal(Stanford Medicine), Edgar Ben‐Josef(University of Michigan–Ann Arbor), Cristina R. Ferrone(Cedars-Sinai Medical Center), Janet E. Murphy(Harvard University), David P. Ryan(East Carolina University), Jennifer Y. Wo(Massachusetts General Hospital), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Harvey J. Mamon(Brigham and Women's Hospital), Jeffrey W. Clark(Massachusetts General Hospital), John T. Mullen(Massachusetts General Hospital), Sam S. Yoon(The University of Texas MD Anderson Cancer Center), Eunice L. Kwak(Harvard University), John A. Wolfgang(Massachusetts General Hospital), Jill N. Allen(Harvard University), Lorraine C. Drapek(Harvard University), Christopher H. Crane(Memorial Sloan Kettering Cancer Center), Beow Y. Yeap(Harvard University), Erin McDonnell(Harvard University)
Cited by 474
Related Papers
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
|Hepatology|2018|4.7k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
AASLD guidelines for the treatment of hepatocellular carcinoma
|Hepatology|2017|4.2k